NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
Clinical Trials
8 trialsNCT04095858 2023-02-08
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT00003056 2021-05-06
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
Takeda
Phase 3 Terminated
NCT03001219 2020-01-29
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
Hoffmann-La Roche
Phase 2 Terminated
NCT02882087 2019-04-03
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
RemeGen Co., Ltd.
Phase 2 Terminated
NCT02862574 2018-06-27
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
Gilead Sciences
Phase 2 Terminated
NCT00517699 2014-08-08
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
Hoffmann-La Roche
Phase 2 Terminated
NCT01283971 2014-02-10
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
Hoffmann-La Roche
Phase 4 Terminated